IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

Cerebellum & Ataxias
Irene Sanz-GallegoJavier Arpa

Abstract

The objective of this clinical open-label trial was to test the safety, tolerability and efficacy of IGF-1 therapy for autosomal dominant cerebellar ataxia (ADCA) patients. A total of 19 molecularly confirmed patients with SCA3, 1 patient with SCA6 and 6 patients with SCA7 completed our study. They were 8 females and 18 males, 28 to 74 years of age (average ± SD: 49.3 ± 14.1). Patients were treated with IGF-1 therapy with a dosage of 50 μg/kg twice a day for 12 months. The efficacy of this therapy was assessed by change from baseline on the scale for the assessment and rating of ataxia (SARA). Ten patients, consecutively selected, continued their assigned dosages in a second year open-label extension trial. A statistically significant improvement in SARA scores was observed for patients with SCA3, patients with SCA7 and all patients grouped together after the first year of IGF-1 therapy, while a stabilization of the disease was confirmed during the second year (extension study). The single patient with SCA6 showed 3 improvement points in SARA score after 3 four-month periods of IGF-1 therapy when compared with baseline measurements. Our data indicate that IGF-1 is safe and well tolerated in general. Our data, in comparison with...Continue Reading

References

Mar 1, 1996·Annals of Neurology·I Torres-AlemanJ Berciano
Mar 14, 1998·Proceedings of the National Academy of Sciences of the United States of America·A M FernandezI Torres-Aleman
Dec 15, 2000·Neurobiology of Disease·S BusiguinaI Torres-Aleman
Dec 19, 2000·Neuroscience and Biobehavioral Reviews·R J SchulingkampR B Raffa
Feb 26, 2004·Lancet Neurology·Suzanne Craft, G Stennis Watson
Apr 23, 2005·The European Journal of Neuroscience·Emilie ColinFrédéric Saudou
Jun 14, 2005·Brain Research. Brain Research Reviews·A M FernandezI Torres-Aleman
Sep 1, 1956·Proceedings of the National Academy of Sciences of the United States of America·R Levi-Montalcini, S Cohen
Feb 10, 2007·Nature Clinical Practice. Neurology·Sub H Subramony
Mar 6, 2007·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Marie MartinTracy Li
May 2, 2007·Human Molecular Genetics·Isabella PalazzoloMaria Pennuto
Feb 8, 2008·Genes, Brain, and Behavior·K SchindowskiL Buée
Jan 15, 2008·Trends in Genetics : TIG·Björn SchumacherJan H J Hoeijmakers
Jan 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Jennifer R GatchelHuda Y Zoghbi
Nov 26, 2008·Neurology·E J SorensonC A Thornton
Aug 8, 2009·Progress in Brain Research·Shilpa RamaswamyJeffrey H Kordower
Dec 17, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Emmanuelle BitounKay E Davies
Oct 21, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Javier ArpaJonas Alex Morales Saute
Mar 21, 2012·Nature Reviews. Neuroscience·Ana M Fernandez, Ignacio Torres-Alemán
Oct 9, 2012·Molecular Neurodegeneration·Carolina FrancoIgnacio Torres-Alemán
Mar 4, 2014·Progress in Neurobiology·Fares BassilWassilios G Meissner
Mar 14, 2014·Proceedings of the National Academy of Sciences of the United States of America·Omar S KhwajaWalter E Kaufmann

❮ Previous
Next ❯

Citations

Jul 25, 2019·Frontiers in Cellular Neuroscience·Wei ChenPing Zheng
Nov 7, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jorge Diogo Da SilvaPatrícia Maciel

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
pregnancy tests

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.